While most people know about CBD and THC, a lesser-known cannabis compound is making waves in oncology research. Cannabigerol (CBG), the “mother of all cannabinoids,” is demonstrating startling anti-cancer properties—particularly against one of medicine’s most aggressive cancers: pancreatic ductal adenocarcinoma.
CBG’s Triple Threat Against Cancer
- Forces Cancer Cells to Self-Destruct
A landmark 2024 study published in International Journal of Molecular Sciences revealed CBG induces autophagic cell death—essentially tricking pancreatic cancer cells into digesting their own damaged components until they collapse. Unlike chemotherapy, which attacks healthy cells too, CBG appears selectively lethal to malignancies. - Shuts Down Cancer’s “Growth Command Center”
Research in PMC shows CBG disrupts the EGFR/AKT/RAS pathways—the same biological “on switches” that make cancers like pancreatic and colorectal tumors so aggressive. By blocking these signals, CBG may starve tumors of their growth potential. - Triggers Programmed Cell Suicide (Apoptosis)
A 2023 preclinical study found CBG upregulated pro-apoptotic genes while suppressing survival signals in glioma cells. This one-two punch makes it a potential adjunct therapy for brain cancers.
The cancer industry has built a $200 billion empire on three brutal pillars: chemotherapy (poison the body and hope the cancer dies first), radiation (burn the tumor and create mutant cells), and surgery (cut it out and pray it doesn’t metastasize). Meanwhile, CBG is doing what these archaic treatments can’t: killing cancer cells without killing the patient.
Why isn’t CBG front-page news? Because it can’t be patented, and it threatens the entire chemotherapy-industrial complex. The NIH holds patents on cannabis as an anticancer agent, yet the DEA still classifies it as a Schedule I drug with “no medical use.” The hypocrisy is staggering.
The evidence is undeniable: CBG works. It’s non-toxic, multi-targeted, and effective against some of the deadliest cancers. So why are patients still being funneled into the same failed treatments?
Because cancer is a business, and CBG is a threat to that business.
Your move, Big Pharma.
Leave a Reply